We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
The clinical trials are indicated for patients with severe and moderate respiratory diseases and they are coordinated by Dr Benito Almirante and Dr Ricard Ferrer.
Vall d'Hebron Barcelona Hospital Campus together with four Spanish hospitals are joining two clinical trials to treat coronavirus cases with Remdesivir, a drug used during the Ebola outbreak in 2014.
Both clinical trials are indicated for patients with severe and moderate respiratory illness. The promoter of the trials is the pharmaceutical company Gilead, which is specialized in antiviral drugs for HIV, hepatitis B and C and influenza. On one hand, patients with moderate respiratory symptoms, diagnosed with Acute Respiratory Distress Syndrome (ARDS) will be studied and supervised under the coordination of Dr. Benito Almirante, Head of the Infectious Diseases Service of the Vall d'Hebron Barcelona Hospital Campus and head of the Infectious Diseases Research group of the Vall d'Hebron Research Institute (VHIR). On the other hand, patients with severe involvement will be studied and supervised by Dr. Ricard Ferrer, head of the Vall d'Hebron Intensive Care Service and head of the Shock, Organic Dysfunction and Resuscitation (SODIR) research group at VHIR.
As indicated by the Minister of Health, Salvador Illa, the analysis processes could take some weeks and obtain a result within a couple of months.
The involved hospitals are: Hospital Clínic de Barcelona, Hospital de Cruces de Bilbao and La Paz de Madrid. The Vall d'Hebron Barcelona Hospital Campus and the hospitals of Alcalà de Henares, Ramón y Cajal and 12 de Octubre of Madrid, as well as Carlos Haya of Málaga are incorporated immediately to the project.
Remdesivir is an antiviral drug that acts inhibiting replication of infected cells and thus preventing the virus from multiplying and spreading. It was developed as a treatment for Ebola virus and infections caused by the Marburg virus. It was later discovered to exhibit reasonable antiviral activity against other viruses, including the respiratory syncytial virus, the Junín virus, the Lassa fever virus, and possibly the coronavirus that causes MERS (Middle East Respiratory Syndrome), the MERS-CoV.
The Minister of Health also explained that the Spanish Medicine Agency has authorized another trial promoted by the AIDS Foundation to treat confirmed non-serious cases. This treatment could be effective as a prevention strategy for people who have been close to confirmed positive patients. Similarly, Illa announced that the World Health Organization (WHO) is also collaborating and preparing a prevention trial for health professionals.
Intensive Care Medicine, General Hospital
Infectious Diseases, General Hospital
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.